Revolutionizing Neurology Testing
Neurocode uses specialized expertise and cutting-edge technologies to provide accurate, repeatable, clinically actionable assays, filling unmet needs in neurodiagnostics.
First-of-its-kind AChR CBA test offered in the U.S.
Offering live cell based assays for antibodies against acetylcholine receptors (AChR CBA)
Myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction (NMJ) in which autoantibodies disrupt the communication between nerves and muscle resulting in fatigable weakness of skeletal muscles.1 Autoantibodies to AChR, MuSK, or LRP4 are found in upwards of 90% of adult MG patients and their detection aids physicians in diagnosis of MG2,3.
Cell based assays are a cutting-edge technology that express proteins in live cultured cells. This technique allows us to cluster AChR on the cell surface, which more closely mimics how it is present in vivo at the NMJ and increases sensitivity even to low-affinity AChR antibodies. CBA are extremely sensitive and may detect autoantibodies in some patients that are seronegative by traditional RIPA4,5,6.
Expertise and excellence in Alzheimer’s disease clinical trials
Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is the most common type of dementia in older adults7. Tracking and diagnosis of AD can be difficult, as the pathological features cannot be directly measured8,9.
Neurocode specializes in state-of-the-art fluid biomarker assays that are revolutionizing AD testing
We have provided our expertise in high-precision ultrasensitive testing to phase 2 and 3 clinical trials. Take advantage of technologies at the forefront of biomarker testing for your secondary endpoint testing or inclusion criteria.